Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.

In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.

At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.

Justin Wheeler, MD, explains how pediatricians can identify constipation across age groups and distinguish overflow incontinence from diarrhea.

Mark R. Corkins, MD, CNSC, FASPEN, AGAF, FAAP, reviews where pediatric probiotic evidence is strongest, why product quality varies, and which children should avoid them.

At AAP 2026, Carmen Tong, DO, discussed evaluating pediatric urinary symptoms and why behavioral strategies often come before medication.

Natalie D. Muth, MD, MPH, RDN, MBA, discusses new dietary guidelines, dairy recommendations, processed foods, and nutrition access for children.

FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.